Boxed Warning Too Strong For Anti-Epileptic Suicidality Signal, Cmte. Says
Executive Summary
While advisory committee members agreed that chronically used anti-epileptic drugs show a signal for suicidality, a majority of the panelists felt a class-wide "black box" warning is too strong to convey the risk
You may also be interested in...
Class Labeling For Anti-epileptics Embraces Lessons From Antidepressants
Anti-epileptic drug sponsors have until mid-January to decide whether to fight FDA-mandated labeling changes and a REMS program after a meta-analysis showed a statistically significant increase in suicidality.
Class Labeling For Anti-epileptics Embraces Lessons From Antidepressants
Anti-epileptic drug sponsors have until mid-January to decide whether to fight FDA-mandated labeling changes and a REMS program after a meta-analysis showed a statistically significant increase in suicidality.
FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality
FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning